Interestingly, an Akt inhibitor, MK-2206 was shown also to synergize with ruxolitinib in cell lines, MPN primary cells and a retroviral reconstitution model of TpoR W515L mutant 40. This evidence concerns the gene AKT1 and myeloproliferative disorder.